Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, Mark Sausen, Rebecca Leary, +60

Science Translational Medicine

Dna AnalysisPathologyVarious Cancer TypesNucleic Acid BiomarkersTumor Biology +15

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Sandra Misale, Rona Yaeger, Sebastijan Hobor, +23

Nature

Kras MutationsMedicineColorectal CancerPathologyAnti-egfr Therapy +5

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Giulia Siravegna, Benedetta Mussolin, Michela Buscarino, +29

Nature Medicine

MedicinePathologyColorectal CancerColorectal Cancer PatientsEgfr Blockade +4

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

Andrea Sartore‐Bianchi, Livio Trusolino, Cosimo Martino, +27

The Lancet Oncology

OncologyMedicinePathologyColorectal CancerDual-targeted Therapy +3

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, +27

Nature Medicine

Tumor BiologyDevelopmental BiologyDistinct Evolutionary PathsMedicineTumor Cells +5

Amplification of the <i>MET</i> Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer

Alberto Bardelli, Simona Corso, Andrea Bertotti, +25

Cancer Discovery

EngineeringPathologyCancer BiologyTumor BiologyCancer Cell Biology +15

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

Giovanni Germano, Simona Lamba, Giuseppe Rospo, +23

Nature

ChromatinGenome InstabilityDna DamageTumour GrowthMedicine +10

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu, +29

Cancer Discovery

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Aparna R. Parikh, Ignaty Leshchiner, Liudmila Elagina, +44

Nature Medicine

Gastrointestinal OncologyTumor HeterogeneityMedicineCancer DetectionGastrointestinal Cancers +9

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation

Noritaka Tanaka, Chendi Li, Meagan B. Ryan, +16

Cancer Discovery